Notice Regarding the Difference of Nonconsolidated Financial Results as Compared to Actual Results for the Previous Year2/13TDnetPDF(508KB)
Sibeprenlimab Phase 3 Data Presented at American Society of Nephrology Kidney Week 202511/10TDnetPDF(292KB)
Consolidated Financial Results for the Nine-Month Period Ended September 30, 2025 [IFRS]10/31TDnetPDF(255KB)
(Progress of Disclosure)Notice of Completion of Share Transfer of Equity-Method Affiliate9/22TDnetPDF(162KB)
Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI9/22TDnetPDF(167KB)
Notice Regarding Partial Amendment to “Notification of Change of Equity Method Affiliate (Transfer of Shares)”8/26TDnetPDF(300KB)
Consolidated Financial Results for the Six-Month Period Ended June 30, 2025 [IFRS]7/31TDnetPDF(815KB)
Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2025 7/29TDnetPDF(244KB)